Cell Signaling Technology Announces Alliance with Merck
News Mar 30, 2007
Cell Signaling Technology, Inc. (CST) has announced an alliance with Merck under which it will provide its patented PhosphoScan® proteomics technology for biomarker discovery and its expertise in antibody development and validation to develop high specificity biomarker assays to help advance Merck’s targeted therapeutic programs for oncology.
CST’s PhosphoScan® technology enables the discovery of drug target phospho-profiles (Phospho-Signatures®) in cells and disease tissues. PhosphoScan®, which involves immunoaffinity purification and mass spectroscopy, was described in the journal Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)).
Discoveries made with PhosphoScan® may provide the basis for biomarker assay development by CST, employing its expertise in antibody and immuno-assay validation. Assays developed under the alliance may be useful within Merck’s drug development programs.
“Our alliance with Merck represents an excellent opportunity for CST to employ its biomarker discovery and development capabilities, integrating PhosphoScan® proteomics with our expertise in antibody development and validation,” said Christopher Bunker, CST’s Director of Business Development.
“We are excited about focusing our PhosphoScan® platform on Merck's targeted inhibitors to identify drug-response Phospho-Signatures® that will guide the development of antibodies for use in cancer profiling studies and biomarker validation.”